MediVax
Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $115M
Overview
A vaccine developer creating novel immunotherapies for infectious diseases and oncology.
Infectious DiseaseOncology
Technology Platform
A platform focused on novel vaccine design and delivery technologies to enhance immunogenicity for both infectious disease and cancer immunotherapy applications.
Funding History
1Total raised:$115M
Series D$115M
Opportunities
Leveraging heightened global focus and funding for vaccine R&D post-pandemic to advance both infectious disease and cancer immunotherapy candidates.
Risk Factors
High risk of clinical failure inherent in vaccine development, particularly for cancer vaccines, which have a historically challenging development path.
Competitive Landscape
Enters highly competitive markets dominated by large-cap vaccine manufacturers and must differentiate through novel antigen selection or delivery technology.